Although EGFR expression was found to promote tumorigenicity and to be a strong indicator for a poor survival prognosis in GBM patients, inactivation of this mutant receptor by cetuximab (a recombinant monoclonal antibody) failed to produce significant clinical benefits in GBM patients [45]. Here, EGFR is linked to glioblastoma.